Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX)
Rhea-AI Filing Summary
Janux Therapeutics filed an 8-K to share fourth-quarter and full-year 2025 results and a business update. The company ended December 31, 2025 with $966.6 million in cash, cash equivalents and short-term investments, down from $1.03 billion a year earlier, providing substantial funding for its pipeline.
Research and development expenses rose to $125.9 million in 2025 from $68.4 million in 2024, while general and administrative expenses were roughly flat at $41.8 million versus $41.0 million. Net loss widened to $157.7 million from $69.0 million, reflecting heavier investment in clinical programs.
Operationally, Janux highlighted continued progress for TRACTr candidates JANX007 in metastatic castration-resistant prostate cancer and JANX008 in solid tumors, as well as the Phase 1 start of JANX011 in healthy volunteers. The company also announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb, including $50 million in upfront and near-term milestone payments and the potential for approximately $800 million in additional milestones plus tiered royalties.
Positive
- Strategic Bristol Myers Squibb collaboration adds $50 million in upfront and near-term milestone payments, with potential for approximately $800 million in additional milestones plus tiered royalties, validating Janux’s tumor-activated platform and offering substantial non-dilutive funding potential.
- Strong liquidity with $966.6 million in cash, cash equivalents and short-term investments as of December 31, 2025, supporting continued advancement of multiple clinical programs across JANX007, JANX008 and JANX011.
Negative
- Significantly higher net loss of $157.7 million for 2025 versus $69.0 million in 2024, driven by a sharp increase in research and development spending, highlights the cash burn associated with Janux’s expanding clinical pipeline.
Insights
Bristol Myers deal and large cash balance support Janux’s expanded R&D push despite rising losses.
Janux Therapeutics reported a larger 2025 net loss of
A key development is the Bristol Myers Squibb collaboration, which brings
For investors evaluating execution risk, the breadth of programs—multiple expansion cohorts for JANX007, ongoing Phase 1 work for JANX008, and the healthy-volunteer study of JANX011—means future disclosures in company filings will be important to assess clinical durability and how fast the company deploys its sizable cash balance.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Press Release of Janux Therapeutics, Inc. dated February 26, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
JANUX THERAPEUTICS, INC. |
|
|
|
|
|
Date: February 26, 2026 |
|
By: |
/s/ David Campbell, Ph.D. |
|
|
|
David Campbell, Ph.D. |
|
|
|
President and Chief Executive Officer |
|
Exhibit 99.1
|
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
SAN DIEGO, February 26, 2026 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
“The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advances. Recent JANX007 clinical results demonstrate clinical activity and a consistent and predictable safety profile in mCRPC and support continued advancement in taxane-naïve patients as well as other expansion cohorts,” said David Campbell, Ph.D., President and CEO of Janux.
“In early 2026, we announced a collaboration with Bristol Myers Squibb that provides near-term capital and further validates the potential of our platform. We also continue to strengthen our team to support the next phase of clinical and pipeline growth. With additional product candidates entering the clinic in 2026, we believe Janux is well positioned to execute on our clinical strategy and continue to build long-term value for patients and shareholders.”
BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS:
Clinical & Pipeline Progress
Strategic Collaboration
Corporate & Leadership
Upcoming Milestones
FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS:
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid tumors. Janux is also advancing its first ARM platform clinical candidate, JANX011, a CD19-ARM for the potential treatment of autoimmune diseases in a Phase 1 study in healthy adult volunteers. Janux continues to generate a number of additional TRACTr, TRACIr, and ARM programs for potential future development. For more information, please visit www.januxrx.com and follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux’s development activities, including its ongoing and planned preclinical studies and clinical trials, and the potential benefits of Janux’s product candidates and platform technologies, expectations regarding the use of Janux’s platform technologies to generate novel product candidates and the strength of Janux’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Janux Therapeutics, Inc.
Condensed Balance Sheets
(in thousands)
|
|
December 31, |
|
|
December 31, |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
52,334 |
|
|
$ |
430,605 |
|
Short-term investments |
|
|
914,233 |
|
|
|
594,568 |
|
Prepaid expenses and other current assets |
|
|
9,320 |
|
|
|
8,493 |
|
Total current assets |
|
|
975,887 |
|
|
|
1,033,666 |
|
Restricted cash |
|
|
816 |
|
|
|
816 |
|
Property and equipment, net |
|
|
3,852 |
|
|
|
4,864 |
|
Operating lease right-of-use assets |
|
|
18,402 |
|
|
|
19,286 |
|
Other long-term assets |
|
|
2,608 |
|
|
|
2,884 |
|
Total assets |
|
$ |
1,001,565 |
|
|
$ |
1,061,516 |
|
|
|
|
|
|
|
|
||
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
4,971 |
|
|
$ |
4,026 |
|
Accrued expenses |
|
|
17,633 |
|
|
|
11,684 |
|
Current portion of operating lease liabilities |
|
|
2,393 |
|
|
|
1,749 |
|
Total current liabilities |
|
|
24,997 |
|
|
|
17,459 |
|
Operating lease liabilities, net of current portion |
|
|
19,746 |
|
|
|
21,276 |
|
Total liabilities |
|
|
44,743 |
|
|
|
38,735 |
|
Total stockholders’ equity |
|
|
956,822 |
|
|
|
1,022,781 |
|
Total liabilities and stockholders’ equity |
|
$ |
1,001,565 |
|
|
$ |
1,061,516 |
|
Janux Therapeutics, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Collaboration revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
10,000 |
|
|
$ |
10,588 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
31,548 |
|
|
|
20,806 |
|
|
|
125,896 |
|
|
|
68,388 |
|
General and administrative |
|
|
10,853 |
|
|
|
8,216 |
|
|
|
41,771 |
|
|
|
41,047 |
|
Total operating expenses |
|
|
42,401 |
|
|
|
29,022 |
|
|
|
167,667 |
|
|
|
109,435 |
|
Loss from operations |
|
|
(42,401 |
) |
|
|
(29,022 |
) |
|
|
(157,667 |
) |
|
|
(98,847 |
) |
Total other income |
|
|
— |
|
|
|
8,806 |
|
|
|
— |
|
|
|
29,853 |
|
Net loss |
|
$ |
(42,401 |
) |
|
$ |
(20,216 |
) |
|
$ |
(157,667 |
) |
|
$ |
(68,994 |
) |
Other comprehensive gain (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized gain (loss) on available-for-sale securities, net |
|
|
10,455 |
|
|
|
(5,668 |
) |
|
|
44,042 |
|
|
|
1,498 |
|
Comprehensive loss |
|
$ |
(31,946 |
) |
|
$ |
(25,884 |
) |
|
$ |
(113,625 |
) |
|
$ |
(67,496 |
) |
Net loss per common share, basic and diluted |
|
$ |
(0.51 |
) |
|
$ |
(0.36 |
) |
|
$ |
(1.83 |
) |
|
$ |
(1.28 |
) |
Weighted-average shares of common stock outstanding, basic and diluted |
|
|
62,145,668 |
|
|
|
56,832,374 |
|
|
|
61,966,999 |
|
|
|
53,751,480 |
|
Contacts
Investors:
Chad Rubin
Endurance Advisors
crubin@enduranceadvisors.com
646.319.3261
Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091
FAQ
How did Janux Therapeutics (JANX) perform financially in 2025?
What is Janux Therapeutics’ cash position as of December 31, 2025?
What collaboration did Janux Therapeutics (JANX) sign with Bristol Myers Squibb?
How are Janux’s key clinical programs, JANX007 and JANX008, progressing?
What is JANX011 and what stage is its clinical development?
How did Janux’s research and development spending change in 2025?
Filing Exhibits & Attachments
2 documentsPress Releases
